Schwerpunkt Logo
Eli Lilly and Company (LLY : NYQ)
Sector: Healthcare | Industry: Drug Manufacturers - General
$1,283.66
+43.32 (+3.49%)
MARKET CAP
$1.14T
FCF YIELD
0.97%
CURRENT PRICE
$1,283.66
P/E RATIO
41.64x
Overview Financial Statements Metrics History DCF Valuation
FILTER LINE ITEMS:
INCOME STATEMENT (ANNUAL - 3-YEAR VIEW)
Financial Line Item 2025-12-31 2024-12-31 2023-12-31
1. REVENUE
Operating Revenue $65.18B $45.04B $34.12B
Total Revenue $65.18B $45.04B $34.12B
2. OPERATING EXPENSES
Reconciled Cost Of Revenue $11.05B $8.42B $7.08B
Interest Expense - $780.60M $485.90M
Tax Provision $5.09B $2.09B $1.31B
Operating Expense $24.43B $19.59B $16.72B
Research And Development $13.34B $10.99B $9.31B
Selling General And Administration $11.09B $8.59B $7.40B
Cost Of Revenue $11.05B $8.42B $7.08B
Total Expenses $35.48B $28.00B $23.80B
3. NET INCOME & EARNINGS DETAILS
Tax Effect Of Unusual Items $-671.52M $-682.55M $-777.47M
Tax Rate For Calcs 19.79% 16.48% 20.10%
Normalized EBITDA $35.09B $22.95B $15.72B
Total Unusual Items $-3.39B $-4.14B $-3.87B
Total Unusual Items Excluding Goodwill $-3.39B $-4.14B $-3.87B
Net Income From Continuing Operation Net Minority Interest $20.64B $10.59B $5.24B
Reconciled Depreciation $2.00B $1.77B $1.53B
EBITDA $31.69B $18.81B $11.85B
EBIT $29.70B $17.04B $10.32B
Net Interest Income - $-605.40M $-312.30M
Interest Income - $175.20M $173.60M
Normalized Income $23.36B $14.05B $8.33B
Net Income From Continuing And Discontinued Operation $20.64B $10.59B $5.24B
Diluted Average Shares 899.30M 904.06M 903.28M
Basic Average Shares 894.80M 897.54M 899.38M
Diluted EPS $22.95 $11.71 $5.80
Basic EPS $23.07 $11.80 $5.83
Diluted NI Availto Com Stockholders $20.64B $10.59B $5.24B
Net Income Including Noncontrolling Interests $20.64B $10.59B $5.24B
Net Income Discontinuous Operations - - -
Net Income Continuous Operations $20.64B $10.59B $5.24B
Pretax Income $25.73B $12.68B $6.55B
Other Income Expense $-3.96B $-4.36B $-3.77B
Other Non Operating Income Expenses $-571.00M $-219.00M $97.00M
Special Income Charges $-3.39B $-4.14B $-3.87B
Gain On Sale Of Business - - -
Other Special Charges $2.91B $3.28B $3.80B
Write Off $484.00M $861.00M $68.00M
Impairment Of Capital Assets - - -
Restructuring And Mergern Acquisition $2.91B $3.28B $45.50M
Gain On Sale Of Security - $-49.50M $-20.20M
Net Non Operating Interest Income Expense - $-605.40M $-312.30M
Interest Expense Non Operating - $780.60M $485.90M
Interest Income Non Operating - $175.20M $173.60M
Operating Income $29.70B $17.04B $10.32B
General And Administrative Expense - $8.59B $7.40B
Other Gand A - $8.59B $7.40B
Salaries And Wages - $-461.70M $-461.90M
Gross Profit $54.13B $36.62B $27.04B
Net Income Common Stockholders $20.64B $10.59B $5.24B
Net Income $20.64B $10.59B $5.24B
FINANCIAL RATIOS & STATS
Financial Metric Value
Trailing P/E 41.64x
Forward P/E 27.19x
Price-to-Book (P/B) 33.78x
Price-to-Sales (P/S) 14.36x
Net Profit Margin (Net Income / Revenue) 33.53%
Operating Profit Margin (EBIT / Revenue) 54.22%
Return on Equity (ROE) 102.29%
Return on Assets (ROA) 20.36%
Dividend Rate $6.92
Dividend Yield 0.54%
Ex-Dividend Date 2026-08-14
Next Earnings Date 2026-10-29